# US 7,335,370 B2 · Chlamydia antigens and corresponding DNA fragments and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,335,370 B2 - Document ID: US7335370B2 - Status: Granted - Kind: B2 - Application number: 10/897,019 - Filed: 2004-07-23 - Published: 2005-01-06 - Granted: 2008-02-26 - Earliest claimed: 1998-12-28 - Assignees: Aventis Pasteur Limited - Inventors: Andrew D. Murdin; Raymond P. Oomen; Joe Wang; Pamela Dunn - Web page: https://patentgrep.com/patent/US7335370B2 ## CPC - G01N 33/56927: {Chlamydia} - C07K 14/295: from Chlamydiales (O) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 2039/53: {DNA (RNA) vaccination} - Y10S 530/811: Peptides or proteins is immobilized on, or in, an inorganic carrier - Y10S 530/814: Cellulose or derivatives thereof - Y10S 530/82: Proteins from microorganisms - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of Chlamydia pneumoniae. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention. ## Claims ### Claim 1 An isolated polypeptide comprising the amino acid sequence set forth as SEQ. ID.NO:2. ### Claim 2 (depends on 1) A fusion protein comprising the polypeptide of claim 1 and a heterologous polypeptide. ### Claim 3 (depends on 2) The fusion protein of claim 2 wherein the heterologous polypeptide is a heterologous signal peptide. ### Claim 4 (depends on 2) The fusion protein of claim 2 wherein the heterologous polypeptide has adjuvant activity. ### Claim 5 (depends on 1) A method for producing the polypeptide of 1 comprising the step of culturing an unicellular host transformed with an expression vector comprising an isolated nucleic acid encoding the polypeptide according to claim 1, thereby producing the isolated polypeptide. ### Claim 6 (depends on 2) A method for producing the fusion protein of claim 2, comprising the step of culturing an unicellular host transformed with an expression vector comprising a nucleic acid encoding the fusion protein of claim 2 thereby producing the isolated fusion protein. ### Claim 7 (depends on 1) A diagnostic kit comprising instructions for use and the polypeptide of claim 1. ### Claim 8 A vaccine comprising an isolated polypeptide comprising the amino acid sequence SEQ. ID.NO:2. ### Claim 9 A vaccine comprising at least one fusion protein, wherein the fusion protein comprises the amino acid sequence of set forth as SEQ. ID NO: 2 and a heterologous polypeptide. ### Claim 10 (depends on 9) The vaccine of claim 9 wherein the heterologous polypeptide is a heterologous signal peptide. ### Claim 11 (depends on 9) The vaccine of claim 9 wherein the heterologous polypeptide has adjuvant activity. ### Claim 12 (depends on 8) The vaccine of claim 8 further comprising an additional polypeptide which enhances the immune response to SEQ ID NO: 2. ### Claim 13 (depends on 8) The vaccine of claim 8 wherein the additional polypeptide comprises a Chlamydia pneumonia polypeptide. ### Claim 14 (depends on 9) The vaccine of claim 9 further comprising an additional polypeptide which enhances the immune response to SEQ ID NO: 2. ### Claim 15 (depends on 9) The vaccine of claim 9 wherein the additional polypeptide comprises a Chlamydia pneumoniae polypeptide. ### Claim 16 (depends on 8) The vaccine of claim 8, further comprising an adjuvant. ### Claim 17 (depends on 1) A pharmaceutical composition comprising the polypeptide according to claim 1 and a pharmaceutically acceptable carrier. ### Claim 18 (depends on 2) A pharmaceutical composition comprising the fusion protein of claim 2 and a pharmaceutically acceptable carrier. ### Claim 19 (depends on 9) The vaccine of claim 9 further comprising an adjuvant. ### Claim 20 (depends on 16) A pharmaceutical composition comprising the vaccine of claim 16 and a pharmaceutically acceptable carrier. ### Claim 21 (depends on 19) A pharmaceutical composition comprising the vaccine of claim 19 and a pharmaceutically acceptable carrier.